High-risk dysmetabolism disorders associated with HAART-treated HIV disease, and reimbursement of lipid-lowering drugs, in a clinical and a socio-economic perspective

AIDS Reviews

Volumn 7, Issue 3, 2005, Pages 155-160

  Manfredi, Roberto ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiretroviral therapy; Health care systems; HIV associated dyslipidemia; Lipid lowering drugs; Prescription; Reimbursement; Risk of cardiovascular events

Indexed keywords

AMPRENAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MEVINOLIN; NELFINAVIR; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SIMVASTATIN; ZIDOVUDINE; HYPOCHOLESTEROLEMIC AGENT;

CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DYSLIPIDEMIA; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ITALY; LIFE EXPECTANCY; METABOLIC DISORDER; MUSCLE DISEASE; OBESITY; PRESCRIPTION; REIMBURSEMENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOCIOECONOMICS; SURVIVAL RATE; CHEMICALLY INDUCED DISORDER; ECONOMICS;

ANTICHOLESTEREMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DYSLIPIDEMIAS; HIV INFECTIONS; HUMANS; ITALY; PRESCRIPTIONS, DRUG; SOCIOECONOMIC FACTORS;

EID: 27944508736     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Graham N. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr 2000;25 (suppl 1):S4-S11.
2. Mulligan K, Grunfeld C, Tai V, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35-43.
3. Distler O, Cooper D, Deckelbaum R, Sturley S. Hyperlipidemia and inhibitors of HIV protease. Curr Opin Clin Nutr Metab Care 2001;4:99-103.
4. Calza L, Manfredi R, Chodo F. Hyperlipidemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents 2003;22:89-99.
5. Paparizos V, Kyriakys K, Botsis C, Papastamopoulos V, Hadjivassiliou M, Stavrianeas N. Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridemia and diabetes mellitus. AIDS 2000;14:903-5.
6. Manfredi R. Management of dyslipidemia in patients with HIV disease. Clin Microbiol Infect 2000;6:579-84.
7. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidemic therapy with bezafibrate. J Infect 2001;42:181-8.
8. Martínez E, Gatell J. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome. Curr Opin Infect Dis 1999;12:13-19.
9. Echevarria K, Hardin T, Smith J. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother 1999;33:859-63.
10. Hirsch H, Battegay M. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management. Infection 2002;30:293-8.
11. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003;17 (suppl 1):S141-8.
12. Dubé M, Stein J, Aberg J, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37:613-27.
13. Sullivan A, Feher M, Nelson M, Gazzard B. Marked hypertriglyceridemia associated with ritonavir therapy. AIDS 1998;12:1393-4.
14. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;160:2060-6.
15. Thiebaut R, Dabis F, Malvy D, Jacqmin-Gadda H, Mercié P, Daucourt Valentin V. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. J Acquir Immune Defic Syndr 2000;23:261-5.
16. Kannel W, Giordano M. Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia. Am J Cardiol 2004;94:901-6.
17. Manfredi R, Calza L, Chiodo F. Gynecomastia, lipodystrophy syndrome, and dyslipidemia occurring or worsening during antiretroviral regimens other than protease inhibitor-based ones. J Acquir Immune Defic Syndr 2003;35:236-8.
18. Manfredi R, Calza L, Chiodo F. An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. J Acquir Immune Defic Syndr 2005;38:236-8.
19. Manfredi R. HIV disease and advanced age. An increasing therapeutic challenge. Drugs Aging 2002;19:647-69.
20. Manfredi R. HIV infection and advanced age. Emerging epidemiological, clinical, and management issues. Ageing Res Reviews 2004;3:31-54.
21. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-86.
22. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
23. D'Arminio Monforte A, Sabin C, Phillips A, et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004;18:1811-7.
24. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62.
25. Passalaris J, Sepkowitz K, Glesby M. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000; 31:787-97.
26. Lewis W. Atherosclerosis in AIDS: potential pathogenetic roles of antretroviral therapy and HIV. J Mol Cell Cardiol 2000;32:2115-29.
27. Hoffmann C, Jaeger H. Cardiology and AIDS-HAART and the consequences. Ann NY Acad Sci 2001;946:130-44.
28. Dronda F, Moreno S, Perez-Elias M, Antela A, Moreno A. Vascular disease in HIV-infected patients: a comparative study of two different therapeutic periods (1994-1997 versus 1998-2000). AIDS 2002;16:1971-3.
29. Rabinstein A. Stroke in HIV-infected patients: a clinical perspective. Cerebrovasc Dis 2003;15:37-44.
30. Mirete G, Masia M, Gutierrez F, Mora A, Escolano C, Maestre A. Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS. Eur J Clin Microbiol Infect Dis 1998;17:810-11.
31. Hadigan C, Meigs J, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-9.
32. Lenhard J, Croom D, Weiel J, Winegar D. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 2000;20:2625-9.
33. Manfredi R, Calza L, Chiodo F. A case-control study of HIV-associated pancreatic abnormalities during HAART era. Focus on emerging risk factors and specific management. Eur J Med Res 2004;9:537-44.
34. Meng O, Lima J, Lai H, et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J 2002;144:642-8.
35. Acevedo M, Sprecher D, Calabrese L, et al. Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: "a call for cardiovascular prevention". Atherosclerosis 2002; 163:349-54.
36. Bucher H, Young J, Battegay M. Protease inhibitor-sparing simplified maintenance therapy: a need for perspective. J Antimicrob Chemother 2004;54:303-5.
37. Drechsler H, Powderly W. Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002;35:1219-30.
38. Fichtenbaum C, Gerber J, Rosenkranz S, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV-seronegative volunteers: ACTG Study A5047. AIDS 2002;16:569-77.
39. Kannel W, Giordano M. Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia. Am J Cardiol 2004;94:901-6.
40. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidemia in HIV-infected patients receiving HAART. AIDS 2003;17:851-9.
41. Bonnet F, Balestre E, Thiébaut R, et al. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. HIV Medicine 2004;5:133-9.
42. Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 2002;30:26-31.
43. Benesic A, Zilly M, Kluge F, et al. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection 2004;32:229-33.
44. Visnegarwala F, Maldonado M, Sajja P, et al. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect 2004:49:283-90.
45. Streja D. Combination therapy for the treatment of dyslipidemia. Curr Opin Investig Drugs 2004;5:306-12.
46. Manfredi R, Motta R, Patrono D, Calza L, Chiodo F, Boni P. A prospective case-control survey of laboratory markers of skeletal muscle damage during HIV disease and antiretroviral therapy. AIDS 2002;16:1969-71.
47. Manfredi R, Calza L, Chiodo F. Polyunsaturated ethyl esters of n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy. J Acquir Immune Defic Syndr 2004;36:878-80.
48. Hobbs F, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002;19:596-604.
49. Vigna G, Fellin R. Dyslipidemia and global cardiovascular risk: treatment guidelines. Ital Heart J 2003;4 (suppl 7):4S-12S.
50. Grundy S, Cleeman J, Merz C, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32.
51. Covington M. Omega-3 fatty acids. Am Fam Physician 2004;70: 133-40.
52. Thompson G. Management of dyslipidemia. Heart 2004;90:949-55.
53. Fazio S, Linton M. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep 2004;6:148-57.
54. Nixon J. Cholesterol management and the reduction of cardiovascular risk. Prev Cardiol 2004;7:34-9.
55. Danielsson B, Vancheri F, Aberg H, Strendler L. Hyperlipidemia: differences in management practices and attitudes in two regions in Europe - Sicily and the Stockholm area. Eur J Epidemiol 1998;14:477-82.
56. Danielsson B. High blood lipids levels - attitudes and management. Different strategies among physicians create uncertainty concerning the therapeutic recommendations. Lakartidningen 2002;99: 1796-7.
57. Joffres M, Kamath T, Williams G, Casey J, Svenson L. Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001. Can J Cardiol 2004;20:767-72.
58. Negredo E, Cruz L, Paredes R, et al. Virologic, immunologic, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002;34:504-10.
59. Manfredi R. Evolution of HIV disease in the third millennium: clinical and related economic issues. Int J Antimicrob Agents 2002; 19:251-3.
60. No Author listed. Ministero della Salute, Agenzia Italiana del Farmaco (AIFA). Le nuove note AIFA 2004. Bollettino d'Informazione sui Farmaci 2004;11:111-3.
61. Giampaoli S, Palmieri L, Chiodini P, et al. The global cardiovascular risk chart. Ital Heart J 2004;5 (suppl):177-85.
62. Calza L, Manfredi R, Chiodo F. Dyslipidemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:10-14.